Interferon alpha-2b improves antitumor effect of hapten DNP-modified autologous tumor vaccine for the treatment of advanced melanoma.
Phase of Trial: Phase III
Latest Information Update: 21 May 2012
At a glance
- Drugs Interferon alpha-2b (Primary) ; Melanoma vaccine DNP-VACC (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 21 May 2012 Planned end date 1 Jan 2010 added as reported by Chinese Clinical Trial Register.
- 20 Dec 2011 New trial record